Production (Stage)
Arrowhead Pharmaceuticals, Inc.
ARWR
$15.13
-$0.26-1.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 545.21M | 2.50M | 3.55M | 19.65M | 35.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 545.21M | 2.50M | 3.55M | 19.65M | 35.47M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 545.21M | 2.50M | 3.55M | 19.65M | 35.47M |
| SG&A Expenses | 130.20M | 125.94M | 122.61M | 119.29M | 117.03M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 663.76M | 628.45M | 604.63M | 566.86M | 509.24M |
| Operating Income | -118.55M | -625.95M | -601.08M | -547.21M | -473.77M |
| Income Before Tax | -152.27M | -648.89M | -612.46M | -548.65M | -478.06M |
| Income Tax Expenses | 2.40M | 649.00K | -2.77M | -1.29M | -546.00K |
| Earnings from Continuing Operations | -154.68 | -649.54 | -609.69 | -547.36 | -477.51 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 10.71M | 9.82M | 10.20M | 8.73M | 6.72M |
| Net Income | -143.97M | -639.71M | -599.49M | -538.64M | -470.79M |
| EBIT | -118.55M | -625.95M | -601.08M | -547.21M | -473.77M |
| EBITDA | -97.43M | -606.38M | -582.49M | -529.78M | -457.85M |
| EPS Basic | -1.36 | -5.15 | -5.00 | -4.65 | -4.24 |
| Normalized Basic EPS | -0.80 | -3.19 | -3.11 | -2.89 | -2.63 |
| EPS Diluted | -1.39 | -5.16 | -5.01 | -4.66 | -4.25 |
| Normalized Diluted EPS | -0.82 | -3.19 | -3.11 | -2.89 | -2.63 |
| Average Basic Shares Outstanding | 506.77M | 496.69M | 479.26M | 462.11M | 444.91M |
| Average Diluted Shares Outstanding | 507.89M | 496.69M | 479.26M | 462.11M | 444.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |